You just read:

Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 21, 2018, 18:00 ET